

Structure VII

wherein:

X''' is X'' or an unsaturated linking group having the structure:



wherein Q is -N= or -CR=, and J is -CR=CR-, -N=CR-, -CR=N-, -O-, -S-, or -NR"-,

thereby incorporating C<sup>9</sup> and C<sup>10</sup> of the rexoid compound into an aromatic (or pseudo-aromatic) ring, and

X', X'', R, R'', Ring, Z, a and b are as defined above.

48. Pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound according to claim 47.

49. Composition according to claim 48, wherein said composition is formulated for oral, topical, intravenous, subcutaneous, intramuscular or intracutaneous administration.

50. A composition according to claim 49, wherein said composition is formulated as a cream, lotion, tablet, dispersible powder, granule, syrup, elixir, sterile aqueous solution, sterile non-aqueous solution, sterile aqueous suspension, sterile non-aqueous suspension, sterile aqueous emulsion or sterile non-aqueous emulsion.

Remarks

By the present communication, claims 1-29 have been canceled and new claims 30-50 are presented for examination. No new matter is introduced by the subject amendment as the amended

claim language is fully supported by the specification and original claims.

The Examiner's attention is drawn to the fact that claim 30 is believed to define the same patentable invention as claim 1 of United States Patent No. 5,219,888.

In view of the above amendments and remarks, prompt consideration on the merits is respectfully requested.

Respectfully submitted,

6/14/94  
Date

Stephen E. Reiter  
Stephen E. Reiter  
Registration No. 31,192  
Telephone: (619) 546-4737  
Facsimile: (619) 546-9392

Pretty, Schroeder,  
Brueggemann & Clark  
444 South Flower Street, Suite 2000  
Los Angeles, California 90071